缬沙坦联合血液透析治疗尿毒症合并顽固性高血压的临床效果

Clinical efficacy of valsartan combined with hemodialysis in the treatment of uremia complicated with refractory hypertension

目的探讨缬沙坦联合血液透析治疗尿毒症合并顽固性高血压的临床效果。方法选择2017年5月至2018年5月我院收治的尿毒症合并顽固性高血压患者82例为研究对象,将患者按照不同治疗方式分为参照组(n=41)与联合治疗组(n=41)。参照组采用血液透析治疗,联合治疗组采用缬沙坦联合血液透析治疗。比较两组患者治疗前、治疗1个月后尿蛋白(Upro)、血尿素氮(BUN)、尿微量白蛋白(mALB)水平及临床疗效。结果治疗1个月后,两组患者的Upro、BUN水平均高于治疗前,mALB水平低于治疗前,且联合治疗组优于参照组(P<0.05)。联合治疗组的治疗总有效率高于参照组(P<0.05)。结论缬沙坦联合血液透析治疗尿毒症合并顽固性高血压的临床效果显著,值得临床推广应用。

Objective To investigate the clinical efficacy of valsartan combined with hemodialysis in the treatment of uremia complicated with refractory hypertension.Methods From May 2017 to May 2018,82 patients with uremia complicated with refractory hypertension admitted in our hospital were selected as the study objects and divided into reference group(n=41)and combined treatment group(n=41)according to different treatment methods.The reference group was treated with hemodialysis,and the combined treatment group was treated with valsartan combined with hemodialysis.The levels of urinary protein(Upro),blood urea nitrogen(BUN)and microalbumin(mALB)before and at 1 month after treatment and treatment effects between the two groups were compared.Results At 1 month after treatment,the levels of Upro and BUN in the two groups were significantly higher than those before treatment,and the levels of mALB were significantly lower than those before treatment,and those in the combined treatment group were better than the control group(P<0.05).The total effective rate of treatment in the combined treatment group was significantly higher than that in the control group(P<0.05).Conclusion The valsartan combined with hemodialysis in the treatment of uremia complicated with refractory hypertension has significant clinical effect,which is worthy of clinical promotion and application.